Venue: Conference Room 3, B1 Floor, The St. Regis Shanghai Jing'an, Shanghai, China
13:30
Registration
13:45 – 14:30
Panel discussion: The trends of domestic and cross-border private finance of innovative pharmaceutical companies and other companies in healthcare industry
Panelists:
Jian CAO, Partner, Shiyu Capital
Richard LI, Legal Director, 6 Dimensions Capital
Diana LI, Partner, Fangda Partners
Wenjun SUN, Vice President of Business Development, JW Biotechnology
Jianxin YANG, Managing Partner, New Hope Medical & Healthcare Fund
14:35-15:20
Panel discussion: The practice and trend of IPOs of pharmaceutical companies in Hong Kong, and the impact by China New Tech Board
Panelists:
Li CHEN, Founder, CEO and Director, Hua Medicine
Xueyan JIANG, Partner, Fangda Partners
Chao LU, Director and Head of China Healthcare Business, CITI
Colin LAW, Partner, Fangda Partners
Fanny YANG, Partner, PwC
15:20-15:40
Tea Break
15:40-16:25
Panel discussion: From clinics to sales – the path and challenge of commercialization of innovative pharmaceutical products
Panelists:
Wei HE, Founder, Genosaber
Libin SHANG, Vice President of China Business Development - China, BeiGene
Josh SHIN, Partner, Fangda Partners
Bin YANG, Executive Director of Investment Department, Zhejiang United Investment Group
Bin YUAN, CBO, CStone Pharmaceuticals
16:30-17:15
Speech: The general trends of investment in innovative medicine and commercialization in China (TBC)
Speaker
Qian LIU, CMO, AstraZeneca
Fangda Partners
Fangda, as a recognized leading PRC law firm, serves both Chinese and international clients successfully in various industries and is continuously involved in, advising on, and creating innovative legal structures for transactions in a broad spectrum of commercial areas. Fangda is one of the few focused and dedicated teams in the pharmaceutical, biotechnology and healthcare sector among the top tier PRC firms, which provides the full range of legal advice to companies, including M&A, foreign direct investment, capital markets, licensing and commercialization, private equity and venture capital, compliance and investigation, intellectual property, regulatory advisory, and antitrust and competition. Fangda has over 600 lawyers and legal professionals in Beijing, Guangzhou, Hong Kong, Shanghai and Shenzhen.
